Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company

Beckton Dickinson’s Q1 Results Affected by Volume-Based Procurement, Life Sciences Growth

Fineline Cube Feb 5, 2024

US-based medical technology company Beckton Dickinson (BD; NYSE: BDX) has reported its financial results for...

Company Drug

SciClone and Menarini File for Import License of Antibacterial Drug Vaborem in Macau

Fineline Cube Feb 5, 2024

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that its Italy-based strategic partner Menarini has submitted...

Company Deals

Baidu Health Partners with Souyao to Boost Offline Pharmacy Services in China

Fineline Cube Feb 5, 2024

Baidu Health has entered into a partnership with Beijing-based pharmaceutical business service provider Souyao. The...

Company

AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability

Fineline Cube Feb 4, 2024

AbbVie (NYSE: ABBV) reported revenues of $54.3 billion for 2023, reflecting a 5.9% year-on-year decline...

Policy / Regulatory

US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions

Fineline Cube Feb 4, 2024

A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...

Company Drug

Biotech Pharmaceutical Secures Approval for Nimotuzumab in Head and Neck Cancer Treatment

Fineline Cube Feb 4, 2024

Sino-Cuban joint venture Biotech Pharmaceutical Limited (BPL) has secured another indication approval in China for...

Company Drug

BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity

Fineline Cube Feb 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding...

Policy / Regulatory R&D

China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates

Fineline Cube Feb 4, 2024

China’s National Cancer Center (NCC) has released the latest national cancer statistics, approved by the...

Company Deals

Johnson & Johnson’s Kenvue Partners with Tencent for Integrated Health Services in China

Fineline Cube Feb 4, 2024

Johnson & Johnson (J&J, NYSE: JNJ)’s consumer health spinoff Kenvue and its Chinese partner Tencent...

Company Drug

Chongqing Genrix Biopharmaceutical Gets NMPA Clearance for IL-4Rα mAb Candidate GR1802

Fineline Cube Feb 4, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has announced that it...

Company Deals Drug

Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004

Fineline Cube Feb 4, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that Sino-US biotech Inmagene Biopharmaceuticals has...

Company Legal / IP

Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval

Fineline Cube Feb 4, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that the New Drug...

Company Deals

Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics

Fineline Cube Feb 4, 2024

Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in...

Company Deals Drug

China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China

Fineline Cube Feb 4, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with...

Company Drug

Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma

Fineline Cube Feb 4, 2024

Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the...

Company

Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels

Fineline Cube Feb 4, 2024

Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the...

Company Drug

Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products

Fineline Cube Feb 4, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...

Company Deals

Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion

Fineline Cube Feb 2, 2024

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S....

Company Drug

Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients

Fineline Cube Feb 2, 2024

Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...

Company Deals

Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development

Fineline Cube Feb 2, 2024

Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan...

Posts pagination

1 … 457 458 459 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.